T1	Participants 45 119	for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6)
T2	Participants 269 325	patients with EGFR mutation-positive lung adenocarcinoma
T3	Participants 411 505	Previously untreated patients with EGFR mutation-positive stage IIIB or IV lung adenocarcinoma
